Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIX NASDAQ:AVTX NASDAQ:CTXR NASDAQ:KPTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$3.52+20.1%$3.10$2.07▼$4.20$96.61M0.5861,894 shs579,631 shsAVTXAvalo Therapeutics$10.14-4.8%$8.26$3.39▼$16.00$140.14M0.88159,656 shs187,343 shsCTXRCitius Pharmaceuticals$1.14-5.8%$1.39$0.65▼$15.25$20.58M1.35465,101 shs288,749 shsKPTIKaryopharm Therapeutics$6.26-2.9%$5.28$3.51▼$16.95$55.93M0.34104,502 shs62,709 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences+20.14%+18.12%+18.52%-4.35%+5.07%AVTXAvalo Therapeutics-4.79%-11.13%+12.42%+126.85%+12.92%CTXRCitius Pharmaceuticals-5.79%-6.56%-14.29%+33.60%-91.23%KPTIKaryopharm Therapeutics-2.95%+0.16%+5.74%+43.58%-45.38%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$3.52+20.1%$3.10$2.07▼$4.20$96.61M0.5861,894 shs579,631 shsAVTXAvalo Therapeutics$10.14-4.8%$8.26$3.39▼$16.00$140.14M0.88159,656 shs187,343 shsCTXRCitius Pharmaceuticals$1.14-5.8%$1.39$0.65▼$15.25$20.58M1.35465,101 shs288,749 shsKPTIKaryopharm Therapeutics$6.26-2.9%$5.28$3.51▼$16.95$55.93M0.34104,502 shs62,709 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences+20.14%+18.12%+18.52%-4.35%+5.07%AVTXAvalo Therapeutics-4.79%-11.13%+12.42%+126.85%+12.92%CTXRCitius Pharmaceuticals-5.79%-6.56%-14.29%+33.60%-91.23%KPTIKaryopharm Therapeutics-2.95%+0.16%+5.74%+43.58%-45.38%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIXAnixa Biosciences 3.00Buy$9.00155.68% UpsideAVTXAvalo Therapeutics 3.00Buy$30.00195.86% UpsideCTXRCitius Pharmaceuticals 2.50Moderate Buy$53.004,549.12% UpsideKPTIKaryopharm Therapeutics 2.80Moderate Buy$34.00443.13% UpsideCurrent Analyst Ratings BreakdownLatest CTXR, KPTI, AVTX, and ANIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025ANIXAnixa BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.009/9/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.009/5/2025AVTXAvalo TherapeuticsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy9/5/2025AVTXAvalo TherapeuticsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy8/19/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/15/2025AVTXAvalo TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight8/13/2025CTXRCitius PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.008/12/2025KPTIKaryopharm TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$42.00 ➝ $25.008/5/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.007/16/2025KPTIKaryopharm TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral7/11/2025KPTIKaryopharm TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$27.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIXAnixa Biosciences$210K551.80N/AN/A$0.59 per share5.97AVTXAvalo Therapeutics$440K303.05N/AN/A$12.80 per share0.79CTXRCitius PharmaceuticalsN/AN/AN/AN/A$10.25 per shareN/AKPTIKaryopharm Therapeutics$145.24M0.37N/AN/A($22.10) per share-0.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIXAnixa Biosciences-$12.55M-$0.35N/A∞N/AN/A-67.45%-59.18%N/AAVTXAvalo Therapeutics-$35.13MN/A0.00N/AN/AN/A-48.48%-35.94%11/6/2025 (Estimated)CTXRCitius Pharmaceuticals-$39.14MN/A0.000.91N/AN/A-60.03%-33.83%N/AKPTIKaryopharm Therapeutics-$76.42M-$14.59N/AN/AN/A-90.02%N/A-84.28%11/4/2025 (Estimated)Latest CTXR, KPTI, AVTX, and ANIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/10/2025Q3 2025ANIXAnixa Biosciences-$0.10-$0.07+$0.03-$0.07N/AN/A8/12/2025Q3 2025CTXRCitius Pharmaceuticals-$0.76-$0.80-$0.04-$0.80$1.92 million$1.92 million8/11/2025Q2 2025KPTIKaryopharm Therapeutics-$3.80-$4.32-$0.52-$4.32$37.92 million$37.93 million8/7/2025Q2 2025AVTXAvalo Therapeutics-$1.43-$1.92-$0.49-$1.92N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIXAnixa BiosciencesN/AN/AN/AN/AN/AAVTXAvalo TherapeuticsN/AN/AN/AN/AN/ACTXRCitius PharmaceuticalsN/AN/AN/AN/AN/AKPTIKaryopharm TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIXAnixa BiosciencesN/A8.458.45AVTXAvalo TherapeuticsN/A12.4412.44CTXRCitius PharmaceuticalsN/A0.470.14KPTIKaryopharm TherapeuticsN/A0.990.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIXAnixa Biosciences29.13%AVTXAvalo Therapeutics87.06%CTXRCitius Pharmaceuticals16.88%KPTIKaryopharm Therapeutics66.44%Insider OwnershipCompanyInsider OwnershipANIXAnixa Biosciences25.30%AVTXAvalo Therapeutics0.25%CTXRCitius Pharmaceuticals10.70%KPTIKaryopharm Therapeutics2.75%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIXAnixa Biosciences532.92 million24.59 millionOptionableAVTXAvalo Therapeutics4013.15 million13.12 millionNot OptionableCTXRCitius Pharmaceuticals2017.01 million15.19 millionOptionableKPTIKaryopharm Therapeutics3808.67 million8.43 millionOptionableCTXR, KPTI, AVTX, and ANIX HeadlinesRecent News About These CompaniesKaryopharm Therapeutics Inc.: Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in MyelofibrosisSeptember 10, 2025 | finanznachrichten.deKaryopharm completes enrollment in Phase 3 Sentry trialSeptember 10, 2025 | msn.comKaryopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in MyelofibrosisSeptember 10, 2025 | prnewswire.comAdage Capital Partners GP L.L.C. Lowers Stake in Karyopharm Therapeutics Inc. $KPTISeptember 10, 2025 | marketbeat.comBirchview Capital LP Decreases Stake in Karyopharm Therapeutics Inc. $KPTISeptember 4, 2025 | marketbeat.comPalo Alto Investors LP Has $1.21 Million Holdings in Karyopharm Therapeutics Inc. $KPTISeptember 4, 2025 | marketbeat.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 2, 2025 | prnewswire.com139,646 Shares in Karyopharm Therapeutics Inc. $KPTI Acquired by T. Rowe Price Investment Management Inc.August 28, 2025 | marketbeat.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Recommendation of "Moderate Buy" from BrokeragesAugust 23, 2025 | marketbeat.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | msn.comKaryopharm’s Earnings Call: Clinical Wins Amid Financial StrainAugust 13, 2025 | msn.comKaryopharm Therapeutics Inc.: Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company ProgressAugust 12, 2025 | finanznachrichten.deKaryopharm Therapeutics: Q2 Earnings SnapshotAugust 12, 2025 | chron.comKaryopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue EstimatesAugust 11, 2025 | zacks.comKaryopharm Therapeutics Inc. (KPTI) Q2 2025 Earnings Call TranscriptAugust 11, 2025 | seekingalpha.comKaryopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company ProgressAugust 11, 2025 | prnewswire.comKaryopharm Therapeutics Inc (KPTI) Q2 2025 Earnings Report Preview: What To ExpectAugust 10, 2025 | finance.yahoo.comEarnings Outlook For Karyopharm TherapeuticsAugust 8, 2025 | benzinga.comKaryopharm to Report Second Quarter 2025 Financial Results on August 11, 2025August 5, 2025 | prnewswire.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2025 | prnewswire.comKaryopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseJuly 29, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 20253 Under-the-Radar Biotechs Under $5 That Could Soar 200%By Chris Markoch | September 9, 2025CTXR, KPTI, AVTX, and ANIX Company DescriptionsAnixa Biosciences NASDAQ:ANIX$3.52 +0.59 (+20.14%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$3.56 +0.04 (+1.16%) As of 09/15/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Avalo Therapeutics NASDAQ:AVTX$10.14 -0.51 (-4.79%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$10.12 -0.02 (-0.15%) As of 09/15/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Citius Pharmaceuticals NASDAQ:CTXR$1.14 -0.07 (-5.79%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$1.15 +0.01 (+0.88%) As of 09/15/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.Karyopharm Therapeutics NASDAQ:KPTI$6.26 -0.19 (-2.95%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$6.22 -0.04 (-0.65%) As of 09/15/2025 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
